People with Down syndrome now live substantially longer due to advances in pediatric care, yet health systems remain poorly equipped to manage the complex needs of aging adults with the condition. Optimizing care for this population requires systematic approaches to age-related comorbidities, screening protocols, and specialist training.
Key Points
- Life expectancy increased from 26 years (1950) to 58 years (2010)
- Pediatric advances addressed congenital heart disease and respiratory infections
- Adult health systems lack adequate protocols for aging Down syndrome population
Longevity Analysis
The extension of lifespan in Down syndrome represents a critical gap between medical capability and clinical infrastructure. While early interventions successfully addressed acute threats to survival, the field has not evolved strategies for managing the cascade of age-related conditions that emerge in adulthood—metabolic dysfunction, cognitive decline, cardiovascular progression, and hormonal shifts. This pattern reflects a broader failure in preventive medicine: identifying and eliminating barriers to healthy aging requires understanding how multiple body systems interact differently in this population, then building consistent, evidence-based monitoring and intervention protocols that anticipate rather than react to deterioration.
Original published by The Lancet Healthy Longevity, by The Lancet Healthy Longevity.